Valproate-risperidone versus valproate-lithium combination in acute mania

ABSTRACT

We evaluated the efficacy of valproate plus risperidone versus valproate plus lithium combination in the treatment of acute mania. In 2-week, randomized, double-blind, parallel group study, 46 acute manic patients according to DSM-IV criteria were randomly assigned to receive combination of valproate 20 mg/ kg/day plus risperidone 2-4 mg/day [n=23] or lithium600-1200 mg/day [n=23]. The assessment of efficacy measures were according to Young Mania Rating Scale [YMRS] and Clinical Global Impressions-Severity [CGI-S] and Improvement [CGI-I] scale. Other effectiveness measures included YMRS response [YMRS reduction >50%] and YMRS remission [YMRS total scores